查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球循環腫瘤細胞 (CTC) 市場
市場調查報告書
商品編碼
1380251

2023-2030 年全球循環腫瘤細胞 (CTC) 市場

Global Circulating Tumor Cells (CTC) Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 195 Pages | 商品交期: 2-3個工作天內

價格

細分市場前景

全球循環腫瘤細胞市場按技術、產品和最終用戶進行細分。根據技術，市場細分為 CTC 檢測和富集方法、CTC 直接檢測方法和 CTC 分析。根據產品，市場細分為試劑盒和試劑、採血管和設備。此外，根據最終用戶，市場細分為醫院和診所、研究和學術機構以及診斷中心。其中，由於奈米技術的發展，CTC檢測和富集方法子領域預計將佔據相當大的市場佔有率，功能化奈米材料修飾的微流控晶片廣泛應用於CTC的富集和檢測。

預計試劑盒和試劑細分市場將在全球循環腫瘤細胞市場中佔據相當大的佔有率

其中，試劑盒和試劑細分市場預計將在全球循環腫瘤細胞（CTC）市場中佔據相當大的佔有率。分段成長歸因於非侵入性培養基試劑盒和試劑在癌症檢測中日益成長的影響力。來自個別患者的腫瘤細胞—透過使研究人員能夠更好地模擬疾病並預測患者對體外治療的反應，有望幫助提高臨床試驗的成功率。該公司的新型現成模組化腫瘤培養基套件旨在使研究人員更容易獲得複雜的癌症模型。例如，2023 年6 月，賽默飛世爾科技(Thermo Fisher Scientific) 在服務科學領域推出了Gibco (TM) OncoPro (TM) 腫瘤培養基試劑盒*，這是第一個專門為擴增患者來源的腫瘤或癌症而開發的商用培養基來自多種癌症適應症的類器官。

區域展望

全球循環腫瘤細胞市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於採用了有效的診斷工具，預計亞太地區將保持相當大的CAGR作為基於CTC 的測試和非侵入性循環腫瘤診斷方法，主要市場參與者包括AnchorDx、Burning Rock Biotech Ltd.、Exact Sciences Corp.、Guardant Health、Otsuka Pharmaceutical Co., Ltd. 等。

北美地區預計將在全球循環腫瘤細胞市場中佔據主導地位

在所有地區中，預計北美地區在預測期內將擁有最大的市場佔有率。區域成長歸因於龐大的患者群體、關鍵參與者的強大存在、藥品的便利性、發達的醫療基礎設施、醫療保健系統中有利的報銷政策、更多的研究、開發和創新活動以及更多地採用先進的循環腫瘤細胞（CTC）技術。區域成長歸因於癌症患者的增加。

根據美國癌症協會（ACS）統計，2023年1月，約有238,340例新發生肺癌病例（男性117,550例，女性120,790例），因肺癌死亡約127,070例（男性67,160例，女性59,910例） 。該地區主要市場參與者的投資增加，以及主要參與者採用各種策略的增加，預計將增加市場機會。主要市場參與者包括 Advanced Cell Diagnostics、Bio-Rad Laboratories, Inc.、Epic Sc​​iences、Ikonisys Inc.、Illumina, Inc. 等。

市場參與者展望

服務循環腫瘤細胞市場的主要公司包括： Bio-Rad Laboratories, Inc.、Illumina, Inc.、Johnson & Johnson、QIAGEN NV、Thermo Fisher Scientific Inc.等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2020 年 10 月，Epic Sc​​iences, Inc. 和 Predicine, Inc. 建立了全球策略合作夥伴關係，為生物製藥公司提供 Predicine 基於 ctDNA 的測試和 Epic 基於 CTC 的測試。 Epic 以 CTC 為基礎的平台提供 AR-V7、AR-N term、PSMA、ER、PR 和其他表現型測試的測試。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 在全球循環腫瘤細胞市場中營運的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Bio-Rad Laboratories, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • QIAGEN NV
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Thermo Fisher Scientific Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Johnson & Johnson Service Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Illumina, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按技術分類的全球循環腫瘤細胞市場
    • CTC 檢測和富集方法
    • CTC直接檢測方法
    • CTC分析
  • 全球循環腫瘤細胞市場（按產品）
    • 試劑盒和試劑
    • 採血管
    • 裝置
  • 最終用戶的全球循環腫瘤細胞市場
    • 醫院和診所
    • 診斷中心
    • 研究和學術機構

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Advanced Cell Diagnostics
  • Akadeum Life Sciences, Inc.
  • BIOCEPT, Inc.
  • BioFluidica, Inc.
  • Biolidics Ltd.
  • Creativ MicroTech, Inc.
  • Epic Sciences
  • Fluxion Biosciences, Inc.
  • Ikonisys Inc.
  • LineaRx, Inc. (Applied DNA Sciences)
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • OncoDiscover
  • Precision Medicine Group, LLC.
  • Sysmex Corporation
  • ScreenCell
  • STEMCELL Technologies, Inc.
Product Code: OMR2027752

Title: Global Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis), by Product (Kits and Reagents, Blood Collection Tubes and Devices), and by End Users (Hospitals and Clinics, Research and Academic Institutes and Diagnostic Centers),Forecast Period (2023-2030).

Global circulating tumor cells market is anticipated to grow at a CAGR of 12.5% during the Forecast Period (2023-2030). Circulating tumor cells (CTC) provide a blood biomarker for early carcinogenesis, cancer progression, and treatment effectiveness. The growing adoption of CTC assays has attracted intense interest as a biomarker that may assist in disease management and is acting as a key supporting factor for the growth of the market globally. Various test offers physicians the ability to serially monitor their patients' response to treatment, especially for circulating tumor monitoring assay, using a simple blood draw, and using those insights to make informed decisions for future care. Hence, the market players are also focusing on introducing circulating tumor cell-based monitoring assays that further bolster market growth. For instance, in January 2023, Foundation Medicine, Inc., in molecular profiling for cancer, and Natera, Inc., in cell-free DNA testing, launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Segmental Outlook

The global circulating tumor cells market is segmented on the technology, product, and end users. Based on the technology, the market is sub-segmented into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. Based on the product, the market is sub-segmented into kits and reagents, blood collection tubes, and devices. Further, based on end users, the market is sub-segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Among the technology, the CTC detection and enrichment methods sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of nanotechnology, microfluidic chips modified with functionalized nanomaterials which are widely used in the enrichment and detection of CTCs.

The Kits and Reagents Sub-Segment is Anticipated to Hold a Considerable Share of the Global Circulating Tumor Cells Market

Among the products, the kits and reagents sub-segment is expected to hold a considerable share of the global circulating tumor cells (CTC) market. The segmental growth is attributed to the growing influence of the non-invasive culture medium kit and reagents in the detection of cancer. Tumor cells derived from individual patients - hold promise in helping improve clinical trial success rates by enabling researchers to better model disease and predict patient response to therapeutics in vitro. Companies' new off-the-shelf, modular tumoroid culture medium kit is designed to make complex cancer models more accessible to researchers. For instance, in June 2023, Thermo Fisher Scientific, in serving science, launched the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.

Regional Outlook

The global circulating tumor cells market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a considerable CAGR owing to the adoption of effective diagnostic tools such as CTC-based tests and non-invasive methods for the diagnosis of circulating tumors. The key market players include AnchorDx, Burning Rock Biotech Ltd., Exact Sciences Corp., Guardant Health, Otsuka Pharmaceutical Co., Ltd., and others.

The North America Region is Expected to Dominant in the Global Circulating tumor cells Market

Among all regions, the North American region is anticipated to have the largest market share over the forecast period. Regional growth is attributed to the presence of a large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, a higher number of researches, development, & innovation activities and higher adoption of advanced circulating tumor cells (CTC) technology. Regional growth is attributed to an increase in cancer patients.

According to the American Cancer Society (ACS), in January 2023, About 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 mortality from lung cancer (67,160 in men and 59,910 in women). The rise in investment by key market players in the region, along with the rise in the adoption of various strategies by the key players is anticipated to increase opportunities in the market. The key market players include Advanced Cell Diagnostics, Bio-Rad Laboratories, Inc., Epic Sciences, Ikonisys Inc., Illumina, Inc., and others.

Market Players Outlook

The major companies serving the circulating tumor cells market include: Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, Epic Sciences, Inc. and Predicine, Inc. entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine's ctDNA-based testing and Epic's CTC-based testing. Epic's CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR, and other phenotypic tests.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global circulating tumor cells market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bio-Rad Laboratories, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. QIAGEN N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Johnson & Johnson Service Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Illumina, Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Circulating Tumor Cells Market by Technology
    • 4.1.1. CTC Detection and Enrichment Methods
    • 4.1.2. CTC Direct Detection Methods
    • 4.1.3. CTC Analysis
  • 4.2. Global Circulating Tumor Cells Market by Product
    • 4.2.1. Kits and Reagents
    • 4.2.2. Blood Collection Tubes
    • 4.2.3. Devices
  • 4.3. Global Circulating Tumor Cells Market by End Users
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research and Academic Institutes

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Cell Diagnostics
  • 6.2. Akadeum Life Sciences, Inc.
  • 6.3. BIOCEPT, Inc.
  • 6.4. BioFluidica, Inc.
  • 6.5. Biolidics Ltd.
  • 6.6. Creativ MicroTech, Inc.
  • 6.7. Epic Sciences
  • 6.8. Fluxion Biosciences, Inc.
  • 6.9. Ikonisys Inc.
  • 6.10. LineaRx, Inc. (Applied DNA Sciences)
  • 6.11. LungLife AI, Inc.
  • 6.12. Menarini Silicon Biosystems
  • 6.13. Miltenyi Biotec
  • 6.14. OncoDiscover
  • 6.15. Precision Medicine Group, LLC.
  • 6.16. Sysmex Corporation
  • 6.17. ScreenCell
  • 6.18. STEMCELL Technologies, Inc.

LIST OF TABLES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CTC ANALYSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CTC ANALYSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY END USERS, 2022 VS 2030 (%)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS and CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. LATIN AMERICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)